I was suprised when I saw that as well. I can't imagine they paid too much for it since the company was in bankrupcy. I wonder if Merck KG just took a feeler on the program since its not costing them much as an avenue for a potential "BioBetter" of Copaxone?
Market Data 
Markets 
AI
